These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37838774)

  • 121. Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.
    Mondal T; Shivange GN; Tihagam RG; Lyerly E; Battista M; Talwar D; Mosavian R; Urbanek K; Rashid NS; Harrell JC; Bos PD; Stelow EB; Stack MS; Bhatnagar S; Tushir-Singh J
    EMBO Mol Med; 2021 Mar; 13(3):e12716. PubMed ID: 33587338
    [TBL] [Abstract][Full Text] [Related]  

  • 122. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
    Upadhyay R; Boiarsky JA; Pantsulaia G; Svensson-Arvelund J; Lin MJ; Wroblewska A; Bhalla S; Scholler N; Bot A; Rossi JM; Sadek N; Parekh S; Lagana A; Baccarini A; Merad M; Brown BD; Brody JD
    Cancer Discov; 2021 Mar; 11(3):599-613. PubMed ID: 33334730
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Author Correction: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.
    Schnell A; Bod L; Madi A; Kuchroo VK
    Cell Res; 2020 Apr; 30(4):366. PubMed ID: 32086475
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Death Receptors and Their Ligands in Inflammatory Disease and Cancer.
    Annibaldi A; Walczak H
    Cold Spring Harb Perspect Biol; 2020 Sep; 12(9):. PubMed ID: 31988141
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Top 10 Challenges in Cancer Immunotherapy.
    Hegde PS; Chen DS
    Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling.
    Pan L; Fu TM; Zhao W; Zhao L; Chen W; Qiu C; Liu W; Liu Z; Piai A; Fu Q; Chen S; Wu H; Chou JJ
    Cell; 2019 Mar; 176(6):1477-1489.e14. PubMed ID: 30827683
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies.
    Bernardes N; Fialho AM
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30518103
    [TBL] [Abstract][Full Text] [Related]  

  • 128. A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
    Shivange G; Urbanek K; Przanowski P; Perry JSA; Jones J; Haggart R; Kostka C; Patki T; Stelow E; Petrova Y; Llaneza D; Mayo M; Ravichandran KS; Landen CN; Bhatnagar S; Tushir-Singh J
    Cancer Cell; 2018 Aug; 34(2):331-345.e11. PubMed ID: 30107179
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
    Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.
    Yeku OO; Purdon TJ; Koneru M; Spriggs D; Brentjens RJ
    Sci Rep; 2017 Sep; 7(1):10541. PubMed ID: 28874817
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance.
    Yamada A; Arakaki R; Saito M; Kudo Y; Ishimaru N
    Front Immunol; 2017; 8():403. PubMed ID: 28424702
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
    Liu W; Ramagopal U; Cheng H; Bonanno JB; Toro R; Bhosle R; Zhan C; Almo SC
    Structure; 2016 Nov; 24(11):2016-2023. PubMed ID: 27806260
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes.
    Chen B; Le W; Wang Y; Li Z; Wang D; Ren L; Lin L; Cui S; Hu JJ; Hu Y; Yang P; Ewing RC; Shi D; Cui Z
    Theranostics; 2016; 6(11):1887-98. PubMed ID: 27570558
    [TBL] [Abstract][Full Text] [Related]  

  • 134. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.
    Tamada T; Shinmi D; Ikeda M; Yonezawa Y; Kataoka S; Kuroki R; Mori E; Motoki K
    Sci Rep; 2015 Dec; 5():17936. PubMed ID: 26672965
    [TBL] [Abstract][Full Text] [Related]  

  • 135. The role of CD95 and CD95 ligand in cancer.
    Peter ME; Hadji A; Murmann AE; Brockway S; Putzbach W; Pattanayak A; Ceppi P
    Cell Death Differ; 2015 Apr; 22(4):549-59. PubMed ID: 25656654
    [TBL] [Abstract][Full Text] [Related]  

  • 136. CD95 and CD95L promote and protect cancer stem cells.
    Ceppi P; Hadji A; Kohlhapp FJ; Pattanayak A; Hau A; Liu X; Liu H; Murmann AE; Peter ME
    Nat Commun; 2014 Nov; 5():5238. PubMed ID: 25366259
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.
    Graves JD; Kordich JJ; Huang TH; Piasecki J; Bush TL; Sullivan T; Foltz IN; Chang W; Douangpanya H; Dang T; O'Neill JW; Mallari R; Zhao X; Branstetter DG; Rossi JM; Long AM; Huang X; Holland PM
    Cancer Cell; 2014 Aug; 26(2):177-89. PubMed ID: 25043603
    [TBL] [Abstract][Full Text] [Related]  

  • 138. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy.
    Melero I; Rouzaut A; Motz GT; Coukos G
    Cancer Discov; 2014 May; 4(5):522-6. PubMed ID: 24795012
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Lentiviral transduction of neuronal cells.
    Wollebo HS; Woldemichaele B; White MK
    Methods Mol Biol; 2013; 1078():141-6. PubMed ID: 23975827
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Conformational coupling across the plasma membrane in activation of the EGF receptor.
    Endres NF; Das R; Smith AW; Arkhipov A; Kovacs E; Huang Y; Pelton JG; Shan Y; Shaw DE; Wemmer DE; Groves JT; Kuriyan J
    Cell; 2013 Jan; 152(3):543-56. PubMed ID: 23374349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.